NovoCure Book Value Per Share Growth & History (NVCR)
NovoCure's book value per share was $3.03 for fiscal 2025.
View full NovoCure company overviewNovoCure annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $3.03 | -$0.29 | −8.81% |
| 2024 | 2024-12-31 | $3.32 | -$0.07 | −1.96% |
| 2023 | 2023-12-31 | $3.39 | -$0.81 | −19.39% |
| 2022 | 2022-12-31 | $4.20 | $0.25 | +6.37% |
| 2021 | 2021-12-31 | $3.95 | -$0.71 | −15.21% |
| 2020 | 2020-12-31 | $4.66 | $2.47 | +112.80% |
| 2019 | 2019-12-31 | $2.19 | $0.98 | +81.78% |
| 2018 | 2018-12-31 | $1.20 | -$0.07 | −5.15% |
| 2017 | 2017-12-31 | $1.27 | -$0.37 | −22.37% |
| 2016 | 2016-12-31 | $1.63 | -$1.36 | −45.39% |
| 2015 | 2015-12-31 | $2.99 | -$4.29 | −58.92% |
| 2014 | 2014-12-31 | $7.29 | -$7.65 | −51.22% |
| 2013 | 2013-12-31 | $14.94 | — | — |
NovoCure quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $2.90 | -$0.22 | −7.11% |
| Q1 2026 | 2026-03-31 | $2.86 | -$0.39 | −12.05% |
| Q4 2025 | 2025-12-31 | $3.03 | -$0.29 | −8.81% |
| Q3 2025 | 2025-09-30 | $3.05 | -$0.29 | −8.67% |
| Q2 2025 | 2025-06-30 | $3.13 | -$0.22 | −6.67% |
| Q1 2025 | 2025-03-31 | $3.25 | -$0.09 | −2.78% |
| Q4 2024 | 2024-12-31 | $3.32 | -$0.07 | −1.96% |
| Q3 2024 | 2024-09-30 | $3.34 | -$0.35 | −9.51% |
| Q2 2024 | 2024-06-30 | $3.35 | -$0.55 | −14.11% |
| Q1 2024 | 2024-03-31 | $3.34 | -$0.73 | −17.94% |
| Q4 2023 | 2023-12-31 | $3.39 | -$0.81 | −19.39% |
| Q3 2023 | 2023-09-30 | $3.69 | -$0.56 | −13.10% |
| Q2 2023 | 2023-06-30 | $3.90 | -$0.32 | −7.54% |
| Q1 2023 | 2023-03-31 | $4.07 | -$0.10 | −2.38% |
| Q4 2022 | 2022-12-31 | $4.20 | $0.25 | +6.37% |
| Q3 2022 | 2022-09-30 | $4.24 | $0.26 | +6.65% |
| Q2 2022 | 2022-06-30 | $4.22 | $0.38 | +10.02% |
| Q1 2022 | 2022-03-31 | $4.17 | $0.56 | +15.59% |
| Q4 2021 | 2021-12-31 | $3.95 | -$0.71 | −15.21% |
| Q3 2021 | 2021-09-30 | $3.98 | $0.96 | +31.86% |
| Q2 2021 | 2021-06-30 | $3.83 | $1.18 | +44.58% |
| Q1 2021 | 2021-03-31 | $3.61 | $1.20 | +49.60% |
| Q4 2020 | 2020-12-31 | $4.66 | $2.47 | +112.80% |
| Q3 2020 | 2020-09-30 | $3.02 | $1.09 | +56.88% |
| Q2 2020 | 2020-06-30 | $2.65 | $1.03 | +63.27% |
| Q1 2020 | 2020-03-31 | $2.41 | $1.09 | +82.52% |
| Q4 2019 | 2019-12-31 | $2.19 | $0.98 | +81.78% |
| Q3 2019 | 2019-09-30 | $1.92 | $0.69 | +55.68% |
| Q2 2019 | 2019-06-30 | $1.62 | $0.41 | +34.02% |
| Q1 2019 | 2019-03-31 | $1.32 | $0.15 | +12.52% |
| Q4 2018 | 2018-12-31 | $1.20 | -$0.07 | −5.15% |
| Q3 2018 | 2018-09-30 | $1.24 | -$0.07 | −5.37% |
| Q2 2018 | 2018-06-30 | $1.21 | -$0.11 | −8.64% |
| Q1 2018 | 2018-03-31 | $1.17 | -$0.29 | −19.74% |
| Q4 2017 | 2017-12-31 | $1.27 | -$0.37 | −22.37% |
| Q3 2017 | 2017-09-30 | $1.31 | -$0.54 | −29.22% |
| Q2 2017 | 2017-06-30 | $1.33 | -$0.85 | −39.05% |
| Q1 2017 | 2017-03-31 | $1.46 | -$1.15 | −43.98% |
| Q4 2016 | 2016-12-31 | $1.63 | -$1.36 | −45.39% |
| Q3 2016 | 2016-09-30 | $1.84 | -$7.91 | −81.08% |
| Q2 2016 | 2016-06-30 | $2.18 | — | — |
| Q1 2016 | 2016-03-31 | $2.61 | — | — |
| Q4 2015 | 2015-12-31 | $2.99 | -$4.29 | −58.92% |
| Q3 2015 | 2015-09-30 | $9.75 | — | — |
| Q4 2014 | 2014-12-31 | $7.29 | — | — |
NovoCure book value per share trends
Over the last five fiscal years, NovoCure's book value per share decreased from $4.66 to $3.03, a change of -$1.63. The latest reported quarter, Q2 2026, shows $2.90.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review NovoCure source filings ↗